Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00036998|
Recruitment Status : Unknown
Verified July 2004 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : November 6, 2013
RATIONALE: Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature.
PURPOSE: Randomized phase II trial to compare the effectiveness of microwave thermotherapy before surgery to that of surgery alone in treating women who have stage I or stage II breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Procedure: conventional surgery Procedure: neoadjuvant therapy Procedure: thermal ablation therapy||Phase 2|
- Compare the safety and efficacy of preoperative focused microwave thermotherapy followed by surgery vs surgery alone in women with early-stage primary breast cancer.
- Compare the reduction of tumor cells at surgical margins and second incision rates in women treated with these regimens.
- Compare the percentage of pathological cell death in women treated with these regimens.
- Compare the amount of surgically removed breast and tumor tissue in women treated with these regimens.
- Compare the measurement of the extent tumor margins of the surgically removed breast and tumor tissue in women treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to tumor classification (T1 vs T2) and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I:Patients undergo ultrasound-guided placement of a microwave sensor and a temperature probe (before or after compression of the breast) and external placement of 2 large opposing microwave emitters and up to 7 skin temperature sensors on the compressed breast. Patients then receive focused microwave thermotherapy that slowly heats the primary breast tumor and deep proximal breast tissue. In the absence of undue heating of the skin, a tumor temperature of 48-52° C is targeted and maintained for an equivalent thermal dose of 140-180 minutes.
Within 60 days of thermotherapy, patients undergo lumpectomy.
- Arm II: Patients undergo lumpectomy only. Patients are followed at 30 and 90 days after surgery, and then at the discretion of the physician.
PROJECTED ACCRUAL: A total of 200-222 patients (100-111 per treatment arm) will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast|
|Study Start Date :||August 2001|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00036998
|United States, California|
|Jonsson Comprehensive Cancer Center, UCLA|
|Los Angeles, California, United States, 90095-1781|
|St. Joseph Hospital Regional Cancer Center - Orange|
|Orange, California, United States, 92868|
|United States, Florida|
|Comprehensive Breast Center of Coral Springs|
|Coral Springs, Florida, United States, 33071|
|United States, Oklahoma|
|Oklahoma University Medical Center at University of Oklahoma Health Sciences Center|
|Oklahoma City, Oklahoma, United States, 73104|
|United States, Tennessee|
|Mroz-Baier Breast Care Center|
|Memphis, Tennessee, United States, 38119|
|United States, Virginia|
|Breast Care Specialists, P.C.|
|Norfolk, Virginia, United States, 23510|
|United States, Washington|
|Tacoma, Washington, United States, 98405|
|Royal Bolton Hospital|
|Bolton, Lancashire, England, United Kingdom, BL4 0JR|
|Study Chair:||William E. Gannon, MD||Celsion|